Oral Oncology
Volume 46, Issue 3 , Pages 172-177 , March 2010

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib

Received 25 August 2009 ,Revised 20 November 2009 ,Accepted 23 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Results presented in part during the 2008 annual meeting of the American Association for Cancer Research (AACR).

PII: S1368-8375(09)00979-8

doi: 10.1016/j.oraloncology.2009.11.010

Oral Oncology
Volume 46, Issue 3 , Pages 172-177 , March 2010

Article Tools

* Image Usage & Resolution